We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Advanced Medical Solutions Group Plc | LSE:AMS | London | Ordinary Share | GB0004536594 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.80 | 2.53% | 194.20 | 193.40 | 194.00 | 195.80 | 189.60 | 191.40 | 454,937 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics,resins,elastomers | 126.21M | 15.89M | 0.0732 | 26.48 | 420.95M |
TIDMAMS
Advanced Medical Solutions Grp PLC
03 November 2015
3 November 2015
Advanced Medical Solutions Group plc
("AMS" or the "Group")
FDA Approves Extended Product Claims for LiquiBand(R) Exceed(TM) Topical Skin Adhesive
Winsford, UK, 3 November 2015 - Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announced that the FDA has approved two new product claims for the octyl formulation product, LiquiBand Exceed(TM) giving it a competitive advantage in the topical skin adhesive market.
These claims will allow AMS and partners to differentiate LiquiBand Exceed(TM) around wound coverage, yield and reuse, providing clinicians with the ability to increase the usage of a single applicator, saving time and cost.
The two new claims include the use of a single device to cover wounds of up to 30cm, as well as a single device being suitable for intraoperative reuse for up to 90 minutes on a single patient. Both claims are unique FDA approved claims for the US Topical Skin Adhesive Market.
Following testing, LiquiBand(R) Exceed(TM) was found to deliver best in class yield to support coverage up to 30cm of wound length(1) , twice the amount advertised by market leading topical skin adhesive products(2) . Due to the proprietary LiquiBand Exceed(TM) formula, the adhesive polymerises via skin contact using naturally occurring skin moisture meaning that the applicator device does not dry out. In-vitro testing proved the device could continually express glue in intervals for up to 90 minutes after device activation.(1)
Chris Meredith, Chief Executive Officer of AMS, commented: "LiquiBand Exceed(TM) has been an excellent addition to our LiquiBand(R) topical skin adhesive portfolio demonstrating encouraging initial uptake since its launch this year. These extended US product claims will help us to continue to provide a superior product for clinicians and a versatile solution for healthcare providers in this key market, in which we are focused on growing our market share."
References:
1. Data on file at Advanced Medical Solutions (Plymouth) Ltd.
2. www.ethicon.com/healthcare-professionals/products/wound-closure/skin-adhesives/dermabond-advanced-topical-skin-adhesive#!description-and-specs
- Ends -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group Tel: +44 (0) plc 1606 545508 Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director Consilium Strategic Communications Tel: +44 (0) 20 3709 5700 Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Ivar Milligan
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal(R) , LiquiBand(R) and RESORBA(R) as well as supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 470 employees. For more information please see www.admedsol.com.
About LiquiBand(R) Exceed(TM)
The LiquiBand(R) portfolio of topical skin adhesives have been developed to provide the global medical market with innovative wound closure products. The LiquiBand(R) devices have been uniquely designed to meet the needs of clinicians and patients for safe, secure and effective topical wound closure.
LiquiBand(R) Exceed(TM) is the newest and most innovative topical skin adhesive to join the LiquiBand(R) family of products. LIQUIBAND Exceed(TM) is a 2-octyl cyanoacrylate adhesive that has a unique felt applicator tip to facilitate even, consistent application. The pure octyl formulation maximizes durability and flexibility while providing high viscosity. LiquiBand(R) Exceed(TM) provides an effective microbial barrier to gram positive, gram negative and fungal microbes. The porous felt applicator tip creates even, consistent application while also preventing squirting and dripping of adhesive. The tip has an elliptical shape to allow for versatility in application technique and can provide wide or narrow application strips.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFFELLSLFIIE
(END) Dow Jones Newswires
November 03, 2015 02:01 ET (07:01 GMT)
1 Year Advanced Medical Solutions Chart |
1 Month Advanced Medical Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions